HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke (Q36107103)

12 August 2017

1 reference

title

HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke (English)

1 reference

12 August 2017

Majaz Moonis

1

1 reference

12 August 2017

M Fisher

series ordinal

2

1 reference

12 August 2017

publication date

1 March 2004

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

241-247

1 reference

Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

Combating hyperthermia in acute stroke: a significant clinical concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

Simvastatin protects against long-lasting behavioral and morphological consequences of neonatal hypoxic/ischemic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

Do statins afford neuroprotection in patients with cerebral ischaemia and stroke?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.241

21 January 2018

Identifiers

DOI

10.1586/14737175.4.2.241

1 reference

12 August 2017

1 reference